Drug Pipeline

BIVV020 (SAR445088) Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
4
Active Studies
2
Recruiting
3
Phase 3
1
Top Sponsors
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-27 NCT06290128
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory…
Trial sites expanded: 125 -> 128 locations
2026-05-19 NCT06290141
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of…
Trial sites expanded: 118 -> 122 locations
Active Studies by Phase
Phase 3
3
Phase 2
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06290128 A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory… Chronic Inflammatory Demyelinating Polyradiculoneuropathy Recruiting
NCT06290141 A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of… Chronic Inflammatory Demyelinating Polyneuropathy Recruiting
NCT06859099 Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP Polyneuropathy, Inflammatory Demyelinating, Chronic Enrolling by Invitation
Phase 2
NCT05156710 BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR) Transplant Rejection Active, Not Recruiting
Sponsors Running BIVV020 (SAR445088) Trials
Get alerts when BIVV020 (SAR445088) trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free